TechNavio: Patent Expiries Will Pave the Way for the Generic Drugs Market in Japan

The Generic Drugs Market in Japan is expected to grow at a CAGR of 8.16% from 2014–2019, says research firm TechNavio.

According to the latest report by TechNavio, the patents of many first-generation approved biopharmaceuticals are set to expire within the forecast period, which will lead to intense competition from generic drugs.

However, due to the economic crisis, major companies in the market have allocated minimal funds for the R&D of innovative drugs, which has hindered the development of new drugs and paved the way for the generic drugs market.

“Pharmaceutical companies developing generic drugs have enormous opportunities to capitalise on the market at this point in time,” says Faisal Ghaus, Vice President of TechNavio.

The new TechNavio report also emphasises an increasing number of mergers and acquisitions, which will help vendors grow and expand their business. For a global company to enter the generic drugs market in Japan, it is important to form a partnership with a local manufacturer.

“In 2014, Teva acquired Taiyo Pharmaceutical, obtaining Taiyo Pharmaceutical’s portfolio of over 550 products. The company also gained access to Taiyo Pharmaceutical’s strong R&D team and local regulatory expertise,” says Ghaus.

Key Information Covered in the Report:

• Market segmentation, size and forecast through 2019
• Market Growth Drivers:
   • Expiry of Patents
   • For a full detailed list, view the report.

• Market Challenges:
   • Intense Competition among Vendors
   • For a full detailed list, view the report.

• Market Trends:
   • Increase in M&A
   • For a full detailed list, view the report.

• Key Vendors:
   • Meiji Seika Pharma Co. Ltd.
   • Nichi-Iko Pharmaceutical Co. Ltd.
   • Nipro Pharma Corp.
   • Sawai Pharmaceuticals Co. Ltd.

• Other Prominent Vendors:
   • Actavis
   • Daiichi Sankyo
   • Daito Pharmaceutical
   • Eisai